← All trials
NCT02960581
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2016
- Primary completion
- Mar 1, 2018
- Completion date
- Mar 1, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 63
- Arms / groups
- 12 / —
- Source
- AACT · pre-existing
Sponsors
- International AIDS Vaccine InitiativeLead sponsor
- Harvard UniversityOverall official - principal investigator
- Ragon Institute of MGH, MIT and HarvardStudy chair
- Ragon Institute of MGH, MIT and HarvardCollaborator
- Harvard UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.